OriCiro Genomics is a Tokyo-based company that develops cell-free synthesis of large-scale genome-scale DNA for advanced therapies and synthetic biology. It closed Series B2 funding of an undisclosed amount.
The investment was made by Asahi Kasei Medical Co., Ltd.
The company plans to increase its growth through this investment by taking advantage of the expected synergies between the two companies in the healthcare sector.
OriCiro’s mission is to develop and commercialize cell-free cell synthesis and amplification technology that generates large genomes for use in gene and other cell-based therapies. The tool is used for research and development in many industries, including agriculture, diagnostics, and food.